Table 1 Baseline characteristics (N = 106).
Overall | GOLD 1 (n = 63) | GOLD 2 (n = 43) | P-value | |
|---|---|---|---|---|
Age (years) | 70.9 ± 6.6 | 72.2 ± 5.4 | 69.0 ± 7.6 | 0.013 |
Sex (male) | 88 (83.0%) | 50 (79.4%) | 38 (88.4%) | 0.342 |
BMI (kg/m2) | 23.6 ± 3.2 | 24.0 ± 2.9 | 23.1 ± 3.6 | 0.15 |
Smoking status | 0.2 | |||
Never | 28 (26.4%) | 20 (31.7%) | 8 (18.6%) | |
Ever | 78 (73.6%) | 43 (68.3%) | 35 (81.4%) | |
mMRC grade | ||||
≥2 | 39 (36.8%) | 23 (36.5%) | 16 (37.2%) | 1.0 |
CAT | ||||
≥ 10 | 76 (71.7%) | 45 (71.4%) | 31 (72.1%) | 1.0 |
Exacerbation in previous year | ||||
≥ 2 moderate or ≥ 1 severe | 3 (2.8%) | 1 (1.6%) | 2 (4.7%) | 0.736 |
Charlson comorbidity index | ||||
≥2 | 12 (11.3%) | 8 (12.7%) | 4 (9.3%) | 0.818 |
Inhaler therapy | 16 (15.1%) | 5 (7.9%) | 11 (25.6%) | 0.027 |
Lung function testing | ||||
FVC (L) | 3.1 ± 0.7 | 3.2 ± 0.7 | 2.9 ± 0.7 | 0.017 |
FVC, %pred | 94.8 ± 14.7 | 101.8 ± 12.2 | 84.5 ± 11.6 | < 0.001 |
FEV1 (L) | 2.0 ± 0.5 | 2.2 ± 0.5 | 1.8 ± 0.4 | < 0.001 |
FEV1, %pred | 84.1 ± 15.8 | 93.8 ± 12.1 | 69.7 ± 7.3 | < 0.001 |
FEV1/FVC (%) | 64.8 ± 6.9 | 67.2 ± 5.6 | 61.2 ± 7.2 | < 0.001 |
PRM value | ||||
PRMfSAD (%) | 24.3 ± 15.0 | 22.1 ± 14.2 | 27.5 ± 15.7 | 0.065 |
PRMemph (%) | 4.3 ± 3.9 | 3.6 ± 3.3 | 5.4 ± 4.6 | 0.022 |
